

<b>Author Year</b> <b>Country</b> <b>PEDro Score</b> <b>Research Design</b> <b>Total Sample Size</b>	<b>Methods</b>	<b>Outcome</b>
<p>Chen et al. 2018 China PCT N=54</p>	<p><b>Population:</b> NMES+carbamazepine group: Mean age=41.8±12.6 yr; Gender: males=25, females=2; Time since injury=31.2±11.5 mo; Level of injury: C=12, T=13, L=2; Severity of injury: AIS A=16, B=3, C=5, D=3; Type of pain=neuropathic.</p> <p>Carbamazepine group: Mean age=43.5±13.7 yr; Gender: males=23, females=4; Time since injury=29.7±10.8 mo; Level of injury: C=14, T=10, L=3; Severity of injury: AIS A=18, B=2, C=3, D=4; Type of pain=neuropathic.</p> <p><b>Intervention:</b> Participants were assigned to either an NMES + carbamazepine group or a carbamazepine only group for 3 mo of treatment with outcomes measures at baseline and post-intervention.</p> <p><b>Outcome Measures:</b> Pain intensity numerical rating scale (NRS), quality of life (QOL) sort form 36 (SF-36) scale, and adverse events.</p> <p>*Neuromuscular electrical stimulation (NMES), neuropathic pain (NPP)</p>	<ol style="list-style-type: none"> <li>1. No significant difference in NRS for NPP or the QOL in SF-36 in the NMES group (p&gt;0.05).</li> <li>2. No serious adverse events in either group.</li> </ol>